FRMD6 was also reported to be upregulated in the poor survival CRC group by unknown causes [44, 46] and is also one of the panel of five key biomarkers of poor prognosis expressed in gastric cancer [47]. This evidence concerns the gene FRMD6 and colorectal carcinoma.